Dan Lender, MD
Endocrinology, Diabetes & Metabolism · Rockwall, TXNPI 1760445274
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 21.8%. Reporting peaked in 2019 at $5,105 and has fallen 99.5% since, to $28 in 2025.
Across 284 payments — averaging $35.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Novo Nordisk AS$2K
- Medtronic$1K
- Eli Lilly$1K
- Mannkind Corporation$519
- Dexcom, Inc.$487
- plus $2K from 33 others
Across 126 payments — averaging $20,869 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2M
- Genentech, Inc.$215K
- Vertex$170K
- Hoffmann-la Roche Limited$74K
- F. Hoffmann-la Roche AG$51K
- Amgen$29K
- plus $94K from 5 others
What the payments were for
- Consulting fees$1,48515%
- Travel & lodging$3,23432%
- Food & beverage$5,05350%
- Education$1291%
- Gifts$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $2,183 |
| Novo Nordisk AS | 7 | $1,538 |
| Medtronic(2 entities) | 21 | $1,485 |
| Eli Lilly | 23 | $1,385 |
| Mannkind Corporation | 30 | $519 |
| Dexcom, Inc. | 25 | $487 |
| Amarin Pharma, Inc. | 24 | $440 |
| Abbott | 14 | $258 |
| AstraZeneca(2 entities) | 11 | $244 |
| AbbVie | 10 | $172 |
| Lilly USA, LLC | 11 | $162 |
| BD | 6 | $135 |
| Bayer | 5 | $85 |
| Boehringer Ingelheim | 5 | $75 |
| Radius Health, Inc. | 4 | $65 |
| Smith+Nephew | 1 | $64 |
| IBSA Pharma Inc. | 4 | $61 |
| Zealand Pharma US, Inc. | 3 | $61 |
| Xeris Pharmaceuticals, Inc. | 4 | $56 |
| Ascensia Diabetes Care US Inc. | 3 | $53 |
| Pfizer | 3 | $48 |
| Insulet Corporation | 2 | $45 |
| Embecta Corp. | 2 | $45 |
| Amneal Pharmaceuticals LLC | 2 | $41 |
| Amgen | 2 | $34 |
| Johnson & Johnson | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Companion Medical, Inc. | 2 | $31 |
| Antares Pharma, Inc. | 2 | $30 |
| Merck | 2 | $29 |
| Valeritas, Inc. | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Nevro Corp. | 1 | $17 |
| GRT US Holding, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Acerus Pharmaceuticals Corporation | 1 | $11 |
| BETA Bionics, Inc. | 1 | $10 |
| Cequr Corporation | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Victoza$1,485
- Minimed 670G System$1,103
How this compares
$10,019 in reported general payments places this provider in the 65th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 66 | $84,762 |
| OzempicSemaglutide | 45 | $60,091 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $42,982 |
| JanuviaSitagliptin Phosphate | 31 | $36,620 |
| MounjaroTirzepatide | 27 | $26,264 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 20 | $21,172 |
| FarxigaDapagliflozin Propanediol | 17 | $21,082 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $20,477 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $19,869 |
| JardianceEmpagliflozin | 26 | $19,735 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $19,286 |
| Humalog Kwikpen U-100Insulin Lispro | 50 | $12,618 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 16 | $11,279 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 76 | $9,058 |
| TradjentaLinagliptin | 12 | $6,825 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $162 | $113,279105 claims |
| Novo NordiskOzempic, Novolog | $2,183 | $63,97557 claims |
| MerckJanuvia, Janumet Xr | $29 | $57,79251 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $75 | $37,83954 claims |
| AstraZenecaFarxiga | $244 | $21,08217 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $41 | $1,00091 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Rockwall
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rocio HarbisonHouston$989K
- Mitchell SorsbyPlano$945K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.